Sandra Calvin, SVP, Chief Accounting Officer: Travere Therapeutics TVTX Planned sale · Filed 09/15

Trade details

Type: Planned sale notice
Stock: Travere Therapeutics TVTX
Person: Sandra CalvinSVP, Chief Accounting Officer
Planned sale date: 26/09/15
Filed: 26/09/15

$353.6K to be sold

Travere Therapeutics trades, last 26 weeks

What else happened in Travere Therapeutics around then

Filed or reported within 30 days of the trade day · 08/16~10/15

Sandra Calvin's recent trades

Sandra CalvinSVP, Chief Accounting Officer
Sell10b5-1 planTravere Therapeutics
Sell10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/16
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned sale10b5-1 planTravere Therapeutics
Planned sale10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/14
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned saleTravere Therapeutics
Planned sale
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03
Sandra CalvinSVP, Chief Accounting Officer
SellTravere Therapeutics
Sell
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03
Sandra CalvinSVP, Chief Accounting Officer
Sell10b5-1 planTravere Therapeutics
Sell10b5-1 plan
Travere Therapeutics
TVTX
$296.1K
7,402 sh
$296.1K
Filed 25/12/29
Traded 25/12/24

Sandra Calvin, CAO — plans to sell 5,375 sh of Travere Therapeutics TVTX · $353.6K · around 09/15 · 10b5-1 plan | Whalegun